The role of sentinel lymph node biopsy in planning adjuvant chemotherapy for elderly women with low risk breast cancer.
Association of Breast Surgery ePoster Library. Blackhall V. 05/13/19; 257056; P012
Ms. Vivienne Blackhall
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P012
Topic: Axilla
Background: Sentinel lymph node biopsy (SLNB) guides the delivery of adjuvant chemotherapy in breast cancer. Elderly patients (≥70 years) may not be candidates for chemotherapy due to poor performance status. Additionally, omitting SLNB in elderly patients with early breast cancer may not affect survival. In patients who are unlikely to receive chemotherapy, SLNB may therefore be unnecessary.Aims: To determine whether SLNB in elderly patients (≥70 years old) with low-risk breast cancer informs adjuvant chemotherapy. Methods :This was a retrospective review of a prospectively maintained database from 2013-2017 at Raigmore Hospital, Inverness. Patients with low-risk unilateral breast cancers undergoing SLNB were included. Basic demographics were recorded. Fisher's exact test compared the difference between the proportion of women with a positive SLNB offered chemotherapy in the younger (<70 years) and older (≥ 70 years) groups. Results: :The study included 492 patients. Median age was 63 years; 137 patients (27.8%) were aged ≥70 years. Eighty-nine patients had a positive SLNB; 73 (82.0%) were < 70 years old and 16 (18.0%) were ≥ 70. Of elderly patients with a positive sentinel node, only 5 were offered chemotherapy (31.2%). In the younger group, most women were offered chemotherapy (89%). There was a statistically significant difference in the proportion of node positive women receiving chemotherapy in the two age defined cohorts (p<0.0001). Conclusions: Elderly women with node positive, low-risk breast cancers are less likely to be offered chemotherapy when compared with younger patients, suggesting that the use of SLNB in elderly patients could be rationalised.
Topic: Axilla
Background: Sentinel lymph node biopsy (SLNB) guides the delivery of adjuvant chemotherapy in breast cancer. Elderly patients (≥70 years) may not be candidates for chemotherapy due to poor performance status. Additionally, omitting SLNB in elderly patients with early breast cancer may not affect survival. In patients who are unlikely to receive chemotherapy, SLNB may therefore be unnecessary.Aims: To determine whether SLNB in elderly patients (≥70 years old) with low-risk breast cancer informs adjuvant chemotherapy. Methods :This was a retrospective review of a prospectively maintained database from 2013-2017 at Raigmore Hospital, Inverness. Patients with low-risk unilateral breast cancers undergoing SLNB were included. Basic demographics were recorded. Fisher's exact test compared the difference between the proportion of women with a positive SLNB offered chemotherapy in the younger (<70 years) and older (≥ 70 years) groups. Results: :The study included 492 patients. Median age was 63 years; 137 patients (27.8%) were aged ≥70 years. Eighty-nine patients had a positive SLNB; 73 (82.0%) were < 70 years old and 16 (18.0%) were ≥ 70. Of elderly patients with a positive sentinel node, only 5 were offered chemotherapy (31.2%). In the younger group, most women were offered chemotherapy (89%). There was a statistically significant difference in the proportion of node positive women receiving chemotherapy in the two age defined cohorts (p<0.0001). Conclusions: Elderly women with node positive, low-risk breast cancers are less likely to be offered chemotherapy when compared with younger patients, suggesting that the use of SLNB in elderly patients could be rationalised.
P012
Topic: Axilla
Background: Sentinel lymph node biopsy (SLNB) guides the delivery of adjuvant chemotherapy in breast cancer. Elderly patients (≥70 years) may not be candidates for chemotherapy due to poor performance status. Additionally, omitting SLNB in elderly patients with early breast cancer may not affect survival. In patients who are unlikely to receive chemotherapy, SLNB may therefore be unnecessary.Aims: To determine whether SLNB in elderly patients (≥70 years old) with low-risk breast cancer informs adjuvant chemotherapy. Methods :This was a retrospective review of a prospectively maintained database from 2013-2017 at Raigmore Hospital, Inverness. Patients with low-risk unilateral breast cancers undergoing SLNB were included. Basic demographics were recorded. Fisher's exact test compared the difference between the proportion of women with a positive SLNB offered chemotherapy in the younger (<70 years) and older (≥ 70 years) groups. Results: :The study included 492 patients. Median age was 63 years; 137 patients (27.8%) were aged ≥70 years. Eighty-nine patients had a positive SLNB; 73 (82.0%) were < 70 years old and 16 (18.0%) were ≥ 70. Of elderly patients with a positive sentinel node, only 5 were offered chemotherapy (31.2%). In the younger group, most women were offered chemotherapy (89%). There was a statistically significant difference in the proportion of node positive women receiving chemotherapy in the two age defined cohorts (p<0.0001). Conclusions: Elderly women with node positive, low-risk breast cancers are less likely to be offered chemotherapy when compared with younger patients, suggesting that the use of SLNB in elderly patients could be rationalised.
Topic: Axilla
Background: Sentinel lymph node biopsy (SLNB) guides the delivery of adjuvant chemotherapy in breast cancer. Elderly patients (≥70 years) may not be candidates for chemotherapy due to poor performance status. Additionally, omitting SLNB in elderly patients with early breast cancer may not affect survival. In patients who are unlikely to receive chemotherapy, SLNB may therefore be unnecessary.Aims: To determine whether SLNB in elderly patients (≥70 years old) with low-risk breast cancer informs adjuvant chemotherapy. Methods :This was a retrospective review of a prospectively maintained database from 2013-2017 at Raigmore Hospital, Inverness. Patients with low-risk unilateral breast cancers undergoing SLNB were included. Basic demographics were recorded. Fisher's exact test compared the difference between the proportion of women with a positive SLNB offered chemotherapy in the younger (<70 years) and older (≥ 70 years) groups. Results: :The study included 492 patients. Median age was 63 years; 137 patients (27.8%) were aged ≥70 years. Eighty-nine patients had a positive SLNB; 73 (82.0%) were < 70 years old and 16 (18.0%) were ≥ 70. Of elderly patients with a positive sentinel node, only 5 were offered chemotherapy (31.2%). In the younger group, most women were offered chemotherapy (89%). There was a statistically significant difference in the proportion of node positive women receiving chemotherapy in the two age defined cohorts (p<0.0001). Conclusions: Elderly women with node positive, low-risk breast cancers are less likely to be offered chemotherapy when compared with younger patients, suggesting that the use of SLNB in elderly patients could be rationalised.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}